| Literature DB >> 33767178 |
Robert W Cross1,2, Zachary A Bornholdt3, Abhishek N Prasad1,2, Viktoriya Borisevich1,2, Krystle N Agans1,2, Daniel J Deer1,2, Dafna M Abelson3, Do H Kim3, William S Shestowsky3, Lioudmila A Campbell3, Elaine Bunyan4, Joan B Geisbert1,2, Karla A Fenton1,2, Larry Zeitlin5, Danielle P Porter6, Thomas W Geisbert7,8.
Abstract
Monoclonal antibodies (mAbs) and remdesivir, a small-molecule antiviral, are promising monotherapies for many viruses, including members of the genera Marburgvirus and Ebolavirus (family Filoviridae), and more recently, SARS-CoV-2. One of the major challenges of acute viral infections is the treatment of advanced disease. Thus, extending the window of therapeutic intervention is critical. Here, we explore the benefit of combination therapy with a mAb and remdesivir in a non-human primate model of Marburg virus (MARV) disease. While rhesus monkeys are protected against lethal infection when treatment with either a human mAb (MR186-YTE; 100%), or remdesivir (80%), is initiated 5 days post-inoculation (dpi) with MARV, no animals survive when either treatment is initiated alone beginning 6 dpi. However, by combining MR186-YTE with remdesivir beginning 6 dpi, significant protection (80%) is achieved, thereby extending the therapeutic window. These results suggest value in exploring combination therapy in patients presenting with advanced filovirus disease.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33767178 PMCID： PMC7994808 DOI： 10.1038/s41467-021-22132-0
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919